Medincell Partner Teva Reports Strong UZEDY® Sales Growth

In Q2 2026, UZEDY® achieved a record net sales of $77 million in the U.S., marking a 43% increase year-on-year. Teva Pharmaceuticals, Medincell's partner, has raised its 2026 revenue outlook for UZEDY® to $270 million–$290 million. UZEDY® remains the fastest-growing long-acting injectable treatment for schizophrenia in the U.S., with prescriptions increasing by 63% year-on-year.

Medincell benefits from the sales through royalties and stands to gain commercial milestone payments of up to $105 million. Additionally, the FDA decision on Teva's once-monthly olanzapine LAI is awaited in Q4 2026. In Europe, the Marketing Authorization Application for olanzapine was accepted in Q2 2026.